• Home
  • Company
    • About Us
    • Management Team
    • Supervisory Board
  • Technology
  • Pipeline
  • Patients
    • Prostate Cancer
    • Clinical Trials
  • Careers
  • Media
    • News & Events
    • Press Releases
  • Contact
Dizy-Logo

  • Bio€quity Europe, Bruges, May 12—14, 2025

    21 March, 2025

  • Innovation for Health, Rotterdam, April 3, 2025

    21 March, 2025

  • MedInvest Biotech & Pharma Investor Conference, New York, March 27-28, 2025

    21 March, 2025

Follow Us

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC

11 February 2021

ModraDoc006/Ritonavir Offers Promising Therapeutic Option for mCRPC, Convenient Approach Amid COVID-19 Pandemic

Article published in ASCO Daily News, February 10 2021

Previous Post Modra Pharmaceuticals Announces First Patients Treated in Phase IIb Metastatic Prostate Cancer Trial
Next Post Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting
Contact
Modra Pharmaceuticals B.V.
Barbara Strozzilaan 201
1083 HN Amsterdam
The Netherlands
Phone: +31 (0)20-205 0188
E-mail: info@modrapharmaceuticals.com
Info
  • Imprint
  • Privacy Policy